Reminyl

Reminyl

galantamine

Manufacturer:

Janssen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Galantamine HBr
Indications/Uses
Mild to moderately severe dementia of the Alzheimer type.
Dosage/Direction for Use
Recommended starting dose: 8 mg daily in the morning for 4 wk. Maintenance dose: Initially 16 mg daily in the morning for at least 4 wk, may be increased to max: 24 mg daily if required. Patient w/ moderate hepatic impairment (Child-Pugh 7-9) Start w/ 8 mg in the morning every other day for at least 1 wk, followed by 8 mg in the morning once daily for at least 4 wk. Max: Not >16 mg daily.
Administration
Should be taken with food.
Contraindications
Special Precautions
Discontinue use at the 1st appearance of skin rash. Not to be used for mild cognitive impairment. CV conditions eg, sick sinus syndrome or other supraventricular cardiac conduction disturbances, patients on drugs that significantly reduce heart rate eg, digoxin & β-blockers; history of ulcer disease or predisposing conditions. Not recommended in patients w/ GI obstruction or recovering from GI surgery. Convulsions; history of severe asthma or obstructive pulmonary disease. Urinary outflow obstruction or recovering from bladder surgery. Monitor patient's wt during therapy. Concurrent NSAIDs use. May affect ability to drive & use machines. Moderate to severe renal impairment. Not recommended in patients w/ CrCl <9 mL/min & severe hepatic impairment (Child-Pugh >9). Pregnancy. Not to be used during lactation. Not recommended in childn.
Adverse Reactions
Decreased appetite; depression; dizziness, headache, tremor, syncope, lethargy, somnolence; bradycardia; nausea, vomiting, diarrhea, abdominal pain & discomfort, upper abdominal pain, dyspepsia; muscle spasms; fatigue, asthenia, malaise; decreased wt; fall, laceration; hallucination; HTN.
Drug Interactions
Increased AUC w/ ketoconazole, paroxetine & erythromycin. Decreased clearance by amitriptyline, fluoxetine, fluvoxamine, paroxetine & quinidine. Increased cholinergic side effects w/ potent CYP2D6 or CYP3A4 inhibitors. Antagonised effect of anticholinergic medication. Exaggerated succinylcholine-type muscle relaxation during anaesth.
MIMS Class
Neurodegenerative Disease Drugs
ATC Classification
N06DA04 - galantamine ; Belongs to the class of anticholinesterases. Used in the management of dementia.
Presentation/Packing
Form
Reminyl PR cap 16 mg
Packing/Price
28's
Form
Reminyl PR cap 8 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in